Insulin Delivery Route for the Artificial Pancreas: Subcutaneous, Intraperitoneal, or Intravenous? Pros and Cons

Insulin delivery is a crucial component of a closed-loop system aiming at the development of an artificial pancreas. The intravenous route, which has been used in the bedside artificial pancreas model for 30 years, has clear advantages in terms of pharmacokinetics and pharmacodynamics, but cannot be used in any ambulatory system so far. Subcutaneous (SC) insulin infusion benefits from the broad expansion of insulin pump therapy that promoted the availability of constantly improving technology and fast-acting insulin analog use. However, persistent delays of insulin absorption and action, variability and shortterm stability of insulin infusion from SC-inserted catheters generate effectiveness and safety issues in view of an ambulatory, automated, glucose-controlled, artificial beta cell. Intraperitoneal insulin delivery, although still marginally used in diabetes care, may offer an interesting alternative because of its more-physiological plasma insulin profiles and sustained stability and reliability of insulin delivery.

[1]  E. Renard,et al.  Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter study , 1995, Diabetes Care.

[2]  R. Hovorka.  Continuous glucose monitoring and closed‐loop systems , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[3]  J. Leahy,et al.  Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas , 2008 .

[4]  P. Oskarsson,et al.  Continuous intraperitoneal insulin infusion partly restores the glucagon response to hypoglycaemia in type 1 diabetic patients. , 2000, Diabetes & metabolism.

[5]  D. Howey,et al.  [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.

[6]  G. Steil,et al.  Closed-loop insulin delivery-the path to physiological glucose control. , 2004, Advanced drug delivery reviews.

[7]  P. I. Shishko,et al.  Comparison of Peripheral and Portal (Via the Umbilical Vein) Routes of Insulin Infusion in IDDM Patients , 1992, Diabetes.

[8]  M. Charles,et al.  Devices for Insulin Administration , 1990, Diabetes Care.

[9]  E. Renard,et al.  Comparison of blood glucose stability and HbA1C between implantable insulin pumps using U400 HOE 21PH insulin and external pumps using lispro in type 1 diabetic patients: a pilot study. , 2002, Diabetes & metabolism.

[10]  N. Wong,et al.  Insulin Antibody Responses After Long-Term Intraperitoneal Insulin Administration via Impiantatile Programmable Insulin Delivery Systems , 1994, Diabetes Care.

[11]  C Jaffiol,et al.  Insulin Underdelivery From Implanted Pumps Using Peritoneal Route: Determinant role of insulin pump compatibility , 1996, Diabetes Care.

[12]  Eric Renard,et al.  Implantable closed-loop glucose-sensing and insulin delivery: the future for insulin pump therapy. , 2002, Current opinion in pharmacology.

[13]  Pharmacokinetics of insulin infused intra-peritoneally via portable pumps. , 1985, Diabete & metabolisme.

[14]  D. Nathan,et al.  Postprandial insulin profiles with implantable pump therapy may explain decreased frequency of severe hypoglycemia, compared with intensive subcutaneous regimens, in insulin-dependent diabetes mellitus patients. , 1996, The American journal of medicine.

[15]  Sélam Jl,et al.  Devices for insulin administration. , 1990 .

[16]  D. Nathan,et al.  Clinical Trial of Programmable Implantable Insulin Pump For Type I Diabetes , 1992, Diabetes Care.

[17]  Eric Renard,et al.  Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients , 2006 .

[18]  A. Caumo,et al.  Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects. , 1993, The Journal of clinical endocrinology and metabolism.

[19]  P. Oskarsson,et al.  Metabolic and hormonal responses to exercise in type 1 diabetic patients during continuous subcutaneous, as compared to continuous intraperitoneal, insulin infusion. , 1999, Diabetes & metabolism.

[20]  Howard Zisser,et al.  OmniPod Insulin Management System , 2006, Diabetes Care.

[21]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[22]  E Renard,et al.  Artificial beta-cell: clinical experience toward an implantable closed-loop insulin delivery system. , 2006, Diabetes & metabolism.

[23]  E. Renard,et al.  Improvement of HbA1c and Blood Glucose Stability in IDDM Patients Treated With Lispro Insulin Analog in External Pumps , 1998, Diabetes Care.

[24]  H. Pitt,et al.  A preliminary trial of the programmable implantable medication system for insulin delivery. , 1989, The New England journal of medicine.

[25]  W Zingg,et al.  Clinical Control of Diabetes by the Artificial Pancreas , 1974, Diabetes.

[26]  David C Klonoff,et al.  The Artificial Pancreas: How Sweet Engineering Will Solve Bitter Problems , 2007, Journal of diabetes science and technology.

[27]  D. Cavadore,et al.  Evaluation of exogenous insulin homoeostasis by the artificial pancreas in insulin-dependent diabetes , 1977, Diabetologia.

[28]  R E Gander,et al.  Comparison of Peripheral and Portal Routes of Insulin Infusion by a Computer-controlled Insulin Infusion System (Artificial Endocrine Pancreas) , 1976, Diabetes.

[29]  H Hanaire-Broutin,et al.  French multicentre experience of implantable insulin pumps. The EVADIAC Study Group. Evaluation of Active Implants in Diabetes Society. , 1994, Lancet.

[30]  P. Blackshear,et al.  Metabolic response to three years of continuous, basal rate intravenous insulin infusion in type II diabetic patients. , 1985, The Journal of clinical endocrinology and metabolism.